NEW YORK, May 01, 2017 (GLOBE NEWSWIRE) -- Motif Bio plc (NASDAQ:MTFB) (AIM:MTFB.LN), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced financial results for the year ended December 31, 2016.
“Motif Bio made significant progress in 2016 towards our goal of bringing our novel antibiotic candidate, iclaprim, to patients with serious and life-threatening infections. The announcement of positive Phase 3 topline results for iclaprim in REVIVE-1 was a major achievement for Motif Bio and we expect to announce the topline data from REVIVE-2, the second Phase 3 trial, in the second half of 2017,” commented Graham Lumsden, CEO of Motif Bio plc.
